April 2020 FDA Recall Drug by B & B Pharmaceuticals, Inc.
D-1244-2020 - cGMP deviations
This Class II drug recall was voluntarily initiated by B & B Pharmaceuticals, Inc. on April 14, 2020 for the product Drug. The FDA reported the reason for recall as cgmp deviations. The product was distributed Nationwide and the recall is currently terminated.
Recall Number: D-1244-2020
cGMP deviations: Presence of foreign material (Teflon)introduced at the production level.
04-14-2020
04-22-2020
3,825 grams
Recall Profile & Regulatory Data
Class II - is a situation in which use of, or exposure to, a violative product may cause temporary or medically reversible adverse health consequences or where the probability of serious adverse health consequences is remote
Enforcement Status About Enforcement Status
Current regulatory stage of the recall event.
Current regulatory stage of the recall event.
Terminated
Recalling Firm About Recalling Firm
The firm responsible for the recall.
The firm responsible for the recall.
B & B Pharmaceuticals, Inc.
Voluntary / Mandated About Voluntary / Mandated
Indicates if the firm acted on its own or under FDA order.
Indicates if the firm acted on its own or under FDA order.
Voluntary: Firm initiated
Drugs
Initial Notification About Initial Notification
Method by which the firm first notified the public.
Method by which the firm first notified the public.
Letter
Distribution Pattern About Distribution Pattern
General area of initial distribution.
General area of initial distribution.
USA Nationwide
07-24-2020
Product Description About Product Description
Full technical description of the product.
Full technical description of the product.
Estradiol, USP (Non-Micronized) (Hemihydrate), packaged in: a) 500 grams (NDC 63275-9900-8), b) 100 grams (NDC 63275-9900-5), c) 25 grams (NDC 63275-9900-4), Distributed by B&B Pharmaceuticals, Inc. 800-499-3100
Batch or Lot Expiration Information
Lot# : 18K26-BB02-PR00553, Reassay 10/09/2023 Product # 700365, 700362 & 700363